Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program
Sanja Mandarića✉, Tarek El Hindia, Eduardo J.M. Nascimentob, Xavier Sáez‐Llorensc, Charissa Borja-Taborad, Heather Friberge, Vianney Tricoua, Nicholas Roubinisa, Raphaël Gottardof, Jeffrey R. Curriere, Mayuri Sharmab, Shibadas Biswalb
- aTakeda Pharmaceuticals International AG
- bTakeda Vaccines, Inc
- cPediatric Infectious Diseases, Hospital del Niño Dr. José Renán Esquivel, Sistema Nacional de Investigación at SENACYT, Centro de Vacunación Internacional (Cevaxin)
- dClinical Research Division, Research Institute for Tropical Medicine
- eViral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research
- fLausanne University Hospital and University of Lausanne
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Despite deployment of vector control and prevention strategies, dengue remains a substantial threat to public health. Development of an effective vaccine against dengue has been challenging due to the need for simultaneous immunity against all four dengue virus serotypes, durable protection regardless of prior dengue exposure, and the complex epidemiological patterns of serotype co-circulation. As part of the clinical development of TAK-003, a live attenuated tetravalent dengue vaccine based on a DENV-2 backbone, extensive profiling of post-vaccination immune responses has been performed in participants who were dengue-naive or previously-exposed at baseline across dengue-endemic and non-endemic regions. In this review, we summarise the magnitude, quality, and functionality of humoral and cellular immune responses following the first and second doses of TAK-003 across age, region, and DENV serotype. We also outline long-term persistence and durability, ongoing investigations into correlates of protection, age-stratified responses, and evidence on co-administration with other vaccines.
TL;DRThe magnitude, quality, and functionality of humoral and cellular immune responses following the first and second doses of TAK-003 across age, region, and DENV serotype are summarized. (Semantic Scholar)